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INTRODUCTION
HIV-infection and chronic hepatitis C is of great concern 
of current infectology [1-2]. The HIV/HCV combined 
co-infection contributes to the progression of liver damage 
and increases the risk of the development of antiretroviral 
therapy side effects [3]. Despite the availability of effective 
treatment, the chronic hepatitis C remains to be one of the 
major, except the opportunistic diseases, causes of mortality 
among HIV-infected individuals [4]. Recently, the correla-
tion between the processes of immunopathogenesis and 
the development of the liver fibrosis, metabolic disorders 
in HIV/HCV-coinfected patients have been actively studied 
with the emphasis on the inherent immunity, namely, the 
TLR genes [2, 4]. The TLR polymorphism is crucial in the 
development of the immune response, since the TLR poly-
morphism-associated dysfunction leads to disturbance of 
identification of the infectious agents and the dysfunction 
of the system of the inherent immunity, thereby causing the 
susceptibility to a wide range of the diseases and peculiarities 
of their progress [5-6]. From the point of view of the HIV/
HCV-coinfection investigation, the TLR4 and TLR7 genes 
are of scientific interest, since the TLR4 interacts with the 
protein layer, structural and nonstructural viral proteins, 
and viral RNA is the TLR7 ligand [4-5, 7-8]. 
Several publications on the study of prevalence of TLR 
polymorphic genotypes, TLR4 Asp299Gly and TLR7 Gln-
11Leu, in particular, among patients with HIV and chronic 
hepatitis C have been found. Thus, according to Т. Kyrychen-
ko et al. (2013), the TLR4 gene Asp299Gly polymorphism 
has been recorded in 12,0 % of HIV-infected people, and 
it presence burdens the progress of the disease [9]; О. de 
Souza Pires-Neto et al. (2015) [10] and A. A. Al-Qahtani et 
al. (2014) [11] report that in patients with chronic hepatitis C 
the frequency of this genotype accounts for 6.9-9.1 %, where-
as, according to C. Guarner-Argente et al. (2010) it reaches 
40.0 % [12]. The prevalence of the TLR7 gene Gln11Leu 
polymorphism among HIV-infected people accounts for 
23.4 % as described in the findings by D. Y. Oh et al. (2009) 
[13], and, according to other authors, in chronic hepatitis C 
it constitutes 15.2-41.7 % and defined gender peculiarities 
of the prevalence [14-17]. It is reported that the presence of 
a polymorphic allele Leu TLR7 in the genome is associated 
with the low rate of liver fibrosis progression in chronic 
hepatitis C [18]. Meanwhile, limited number of publications 
on the study of the prevalence of the abovementioned poly-
morphisms among HIV/HCV-coinfected people has been 
found: Yurko K. (2016) describes the frequency of recording 
of the TLR4 Asp299Gly genotype at the level of 17.0 % and its 
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effect on the metabolic processes in this category of patients 
[2], and data on the prevalence of the TLR7 gene Gln11Leu 
polymorphism are not presented at all. 
Consequently, current scientific data show that occur-
rence of the abovementioned polymorphisms in HIV/
HCV-coinfected people can influence on the clinical course 
of the disease, and their study will be promising in terms of 
individualization of the diagnostic and therapeutic approach 
for the infection, making the investigation to be relevant.
THE AIM
The paper is aimed at the study of the prevalence of the of TLR4 
gene Gly and TLR7 gene Leu polymorphic alleles among patients 
with HIV/HCV-coinfection in general and with regard to gender, as 
well as to determine their role in the development of the infection. 
MATERIAL AND METHODS
To achieve the objective of the research a cohort and 
case-control study has been carried out. The total of 535 
people has been examined, including: 
-  HIV/HCV-coinfected: 104 subjects; males – 77 (74.0 
%), females – 27 (26.0 %) aged 17 to 51 years; average 
– 34.0±0.6 (Main Group);
-  HIV-monoinfected: 90 subjects; males – 58 (64.4 %), 
females – 32 (35.6 %) aged 21 to 55 years; average – 
34.9±0.8 (comparison Group I);
-  patients with chronic hepatitis C: 166 subjects; males – 
111 (66.9 %), females – 55 (33.1 %) aged 20 to 63 years; 
average – 40.3±0.7 (comparison Group I); 
-  healthy people: for TLR4 gene: 90 subjects; males – 50 
(55.6 %), females – 40 (44.4 %) aged 18 to 33 years; 
average – 19.5±0.2 and for TLR7 gene: 85 subjects; 
males – 47 (55.3 %), females – 38 (44.7 %) aged 20 to 
67 years; average – 30.1±1.4 (population control group). 
Chronic hepatitis C and HIV have been diagnosed in 
compliance with the International Classification of Dis-
eases, 10th Edition, and verified by the detection of spe-
cific serological and molecular biological markers of the 
infections (for chronic hepatitis C: detection of the HCV 
IgG antibodies in the blood by the ELISA method and 
HCV-RNA by the RT-PCR method) with genetic typing; 
for HIV-infection: detection of the antibodies to HIV in the 
blood by the ELISA method). Similarly, the occurrence of 
chronic hepatitis C in HIV-infected people has been con-
firmed in patients with HCV-monoinfection. Clinical and 
laboratory examination of the patients has been carried out 
at Poltava Regional Infectious Hospital, Poltava Regional 
Center for HIV/AIDS prevention and private laboratories. 
All patients have been provided with genetic tests. TLR4 
Asp299Gly polymorphic area has been genetically typed by 
the PCR, using the specific oligonucleotide primers, on the 
«Tertsik» amplifier («NPO DNA-Technology», LTD, Rus-
sia) and TLR7 Gln11Leu polymorphic area by the method 
of allele-specific RT-PCR on the «DT Light» amplifier 
(«NPO DNA-Technology», LTD, Russia) at the Research 
Institute for Genetic and Immunological Grounds of Pa-
thology and Pharmacogenetics of the HSEEU «Ukrainian 
Medical Stomatological Academy». 
Statistical analysis of the findings has been carried out 
using the «SPSS 23.0» (USA) program. The allele frequen-
cies have been compared by the analysis of contingency 
tables using the Fisher’s exact test (FET) and the χ2 test 
depending on the baseline conditions of the analysis. The 
risk of the pathology development has been estimated 
by the calculation of the odds ratio (OR) and its 95 % 
confidence interval (CI) using the method of univariate 
logistic regression, where 95 % CI characterizes the degree 
of data validity, and the p-value indicates the probability of 
deviation from of null hypothesis. OR=1 was regarded as 
the null hypothesis, OR>1 – high risk, OR<1 – low risk for 
pathology development. The differences were considered 
reliable in р<0.05; the tendency to reliability was consid-
ered in р<0.1. 
RESULTS AND DISCUSSION
The study has been established that carriers of both normal 
(Asp299Asp TLR4, among women – Gln11Gln, among 
men – Gln11/- TLR7) and polymorphically modified (As-
p299Gly TLR4, among women – Gln11Leu and Leu11Leu, 
among men – Leu11/- TLR7) genotypes of investigated 
genes have been recorded among patients of main and 
comparison groups. The overall prevalence of genotypes 
and alleles of the TLR4 gene is shown in table І. 
Data of the table І show that homozygous polymorphic 
TLR4 gene Gly299Gly genotype has not been found among 
the examined groups, which is consistent with the publi-
cation data as for its low frequency in the population [2, 
9-10, 18-20].
The frequency of TLR7 genotype registration, taking 
into account gender specificities due to its X-chromosomal 
localization [13-14], as well as the general prevalence of 
the alleles of this gene, are presented in table ІІ.
Taking into account the lack of carriers of the polymor-
phic homozygous Gly299Gly genotype of the TLR4 gene 
as well as the low overall frequency of the registration of 
the Leu11Leu and Leu11/- TLR7 genotypes, limiting the 
possibility of statistical aggregation, when comparing the 
signs, the subjects examined in groups were united on 
the basis of the carrier of the polymorphic alleles of the 
subjects genes.
The comparative analysis of the distribution of TLR4 
genes polymorphic alleles, made between patients and 
healthy people has established statistically significant 
differences regarding the TLR4 gene Gly polymorphic 
allele, which gives the grounds to consider its presence as 
the risk factor for HIV-infection and chronic hepatitis C 
development (table ІІІ). 
Data of the Table ІІІ show that among patients with HIV/
HCV-coinfection the frequency of the TLR4 gene Gly allele 
accounts for 23.1 %, that 7 times higher than the same index 
in the population controls ‒ 3.3 % (р=0.000). The OR calcu-
lation has established that carryability of this allele increases 
the risk of coinfection by 9 times (OR=8.70 [95 % 2.52-30.0], 
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р=0.000). The findings were confirmed during the study of 
the prevalence of the polymorphic allele of this gene among 
patients with HIV-monoinfection and chronic hepatitis C, 
where it has been recorded with similar, significantly higher 
frequency in contrast to healthy individuals ‒ 14.4 % (р=0.000) 
and 14.5 % (р=0.005), respectively). The OR calculation shows 
that in carriers of TLR4 gene Gly allele the risk of HIV and 
chronic hepatitis C development, in case of infection, increases 
by 5 times (OR=4.89 [95 % 1.35-17.82], р=0,016 and OR=4.9 
[95 % CI 1.43-16.76], р=0.011, respectively). 
No difference in the frequency of the TLR7 gene 
Leu allele among patients with HIV/HCV-coinfection, 
HIV-monoinfection, chronic hepatitis C and healthy peo-
ple of population control has been found ‒ 26.0 %, 28.9 %, 
19.9 % and 25.9 %, respectively to groups (р>0.05), the OR 
calculation was statistically insignificant, too, indicating 
about the absence of its impact on the development of the 
abovementioned infections. 
The next stage of the study included the comparative 
analysis of the frequencies of the TLR4 and TLR7 genes 
polymorphic alleles among the groups of patients (Figure 1).
The Figure 1 shows that among HIV/HCV-coinfected 
patients the TLR4 gene Gly allele has been recorded more 
frequently than in chronic hepatitis C and HIV-monoinfec-
tion; however, the tendency to reliability of difference has 
been noted only in chronic hepatitis C (χ2=3.25, р=0.071). 
No differences in the TLR7 Leu allele frequency has been 
found during the comparison between the groups.  
Subsequently, it was appropriate to carry out the analysis of 
the prevalence of the TLR4 and TLR7 genes polymorphic alleles 
among patients and healthy people with regard to its gender, 
which revealed absence of gender differences in the frequency of 
records of the TLR4 gene Gly polymorphic allele and significant 
prevalence of the TLR7 gene Leu allele among female patients 
both with HIV/HCV-coinfection, HIV-monoinfection, chronic 
hepatitis C and healthy women (Figure 2). 
Table І. The frequency of record of TLR4 gene alleles аnd genotypes among patients with HIV/HCV-coinfection, HIV-monoinfection, chronic hepatitis C 
and healthy people
Groups
TLR4
Genotype, abs. number (%) Allele, abs. number (%)
Asp299Asp Asp299Gly Gly299Gly Asp Gly
HIV/HCV (n=104) 80 (76.9) 24 (23.1) - 184 (88.5) 24 (11.5)
HIV (n=90) 77 (85.6) 13 (14.4) - 167 (92.8) 13 (7.2)
Chronic hepatitis C (n=166) 142 (85.5) 24 (14.5) - 308 (92.7) 24 (7.3)
Healthy people (n=85) 87 (96.7) 3 (3.3) - 177 (98.3) 3 (1.7)
Table ІІ. The frequency of record of TLR7 gene alleles аnd genotypes among patients with HIV/HCV-coinfection, HIV-monoinfection, chronic hepatitis 
C and healthy people 
Groups
TLR7
Genotype, abs. number (%) Allele,
abs. number (%)Females Males
Gln11Gln Gln11Leu Leu11Leu Gln11/- Leu11/- Gln Leu
HIV/HCV 
(n=104)
12 
(44.4)
14 
(51.9)
1 
(3.7) 65 (84.4) 12 (15.6)
103 
(78.6) 28 (21.4)
HIV 
(n=90)
15 
(46.9)
12
(37.5)
5
(15.6) 49 (84.5)
9 
(15.5)
91 
(74.6) 31 (25.4)
Chronic hepatitis C 
(n=166)
38 
(69.1)
15
(27.3)
2
(3.6) 95 (85.6) 16 (14.4)
186 
(84.1) 35 (15.9)
Healthy people 
(n=85)
23 
(60.5)
12 
(31.6)
3 
(7.9) 40 (85.1)
7 
(14.9) 98 (79.7) 25 (20.3)
Table ІІІ. The frequency of record of TLR4 gene alleles among patients with HIV/HCV -coinfection, HIV-monoinfection, chronic hepatitis C and healthy people
Polymorphic allele 
carrier 
Groups, abs. number (%) р
HIV/HCV HIV Chronic hepatitis C Healthypeople р1=0.000
р2=0.015
р3=0.005
Absence of allele Gly 80 (76.9) 77 (85.6) 142 (85.5) 87 (96.7)
Presence of allele Gly 24 (23.1) 13 (14.4) 24 (14.5) 3 (3.3)
Note. р – significance value obtained using the FET while comparing the groups of patients and healthy people: р1 – HIV/HCV-coinfected/healthy, р2 – 
HIV-monoinfected/healthy, р3 – chronic hepatitis C/healthy.
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The Figure 2 shows that among women with HIV/HCV-coin-
fection the TLR7 gene Leu polymorphic allele has been recorded 
by 3.6 (χ2=16.61, р=0.000); with HIV-monoinfection by 3.4 
(р=0.000); with chronic hepatitis C by 2.1 (χ2=6.28, р=0.012) and 
in controls by 2.7 (р=0.013) times more frequently than in men 
which is connected to X-chromosome localization of the gene.
Note. р – significance value obtained using the χ2 test.
Figure 1. The frequencies of the TLR4 and TLR7 genes polymorphic alleles in patients with HIV/HCV-coinfection, HIV-monoinfection and chronic hepatitis C 
Note. * – p<0.05 (significance value obtained using the χ2 test and FET depending on the baseline conditions of the analysis).
Figure 2. Gender distribution of the ТLR4 and ТLR7 polymorphic alleles in patients with HIV/HCV-coinfection, HIV-monoinfection, chronic hepatitis C 
and healthy people 
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CONCLUSIONS 
1.  The prevalence of the TLR4 gene Gly polymorphic allele 
among patients with HIV/HCV-coinfection, HIV-monoin-
fection and chronic hepatitis C accounted for 23.1 %, 14.4 % 
and 14.5 %, respectively, which is significantly higher than 
the similar index in controls – 3.3 % (р=0.000, р=0.015 and 
р=0.005, respectively). 
2.  The presence of the TLR4 gene Gly polymorphic allele in 
the genome increases the risk of HIV/HCV-coinfection 
development, in case of infection, by 9 (OR=8.70, р=0.000), 
HIV-monoinfection and chronic hepatitis C by 5 (OR=4.89, 
р=0.015 and OR=4.90, р=0.011, respectively) times. 
3.  TLR7 gene Leu polymorphic allele is recorded with the 
frequency of 19.9-26.0 % in patients with HIV/HCV-coin-
fection, HIV-monoinfection and chronic hepatitis C as 
compared to controls (25.9 %, р>0.05).
4.  In female patients with HIV/HCV-coinfection, 
HIV-monoinfection, chronic hepatitis C and healthy indi-
viduals the TLR7 gene Leu polymorphic allele is recorded 
by 2.1-3.6 times more frequently than in male patients 
(р=0.000, р=0.000, р=0.012 and р=0.013, respectively). 
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